CA
AMPH icon

CoreCap Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

CoreCap Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-107
Closed -$2.1K – 3174
2026
Q1 		$2.1K Hold
107
– – ﹤0.01% 2404
2025
Q4 		$2.87K Hold
107
– – ﹤0.01% 2376
2025
Q3 		$2.85K Buy
107
+48
+81% +$1.24K ﹤0.01% 2308
2025
Q2 		$1.35K Hold
59
– – ﹤0.01% 2380
2025
Q1 		$1.71K Hold
59
– – ﹤0.01% 2403
2024
Q4 		$2.19K Hold
59
– – ﹤0.01% 2199
2024
Q3 		$2.86K Hold
59
– – ﹤0.01% 2111
2024
Q2 		$2.36K Buy
+59
New +$2.44K ﹤0.01% 1294

Other funds holding AMPH

LG
LAM Group Lake Oswego, Oregon $201M AUM 22.35% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SWP
Significant Wealth Partners Cary, Illinois $92.4M AUM 9.22% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
1IA
1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

CoreCap Advisors's AMPH Position: Q2 2026 in Review

CoreCap Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 107 shares — an estimated $2.1K sold.

CoreCap Advisors first reported a position in AMPH in Q2 2024 and held it in 8 quarters. The position peaked at $2.87K in Q4 2025. 20 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • CoreCap Advisors reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • CoreCap Advisors sold 107 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $2.1K.
  • CoreCap Advisors first reported a position in Amphastar Pharmaceuticals in Q2 2024 and held it in 8 quarters.
  • CoreCap Advisors's Amphastar Pharmaceuticals position peaked at $2.87K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.